skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
NA-17/MAGE-3.A2/NY-ESO-1 Peptide Vaccine (Code C96042)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: NA-17/MAGE-3.A2/NY-ESO-1 Peptide Vaccine

Definition: A peptide cancer vaccine consisting of peptides derived from the melanoma antigen NA-17, the human leukocyte antigen HLA-A2-restricted human melanoma antigen 3 (MAGE-3.A2) and the cancer-testis antigen (NY-ESO-1), with potential immunostimulating and antineoplastic activities. Upon administration, the NA-17/MAGE-3.A2/NY-ESO-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing NA-17, MAGE-3.A2 and NY-ESO-1, resulting in tumor cell lysis. The tumor-associated antigens (TAAs) NA-17, MAGE-3.A2 and NY-ESO-1 are overexpressed in a variety of cancer cell types.

Label: NA-17/MAGE-3.A2/NY-ESO-1 Peptide Vaccine

NCI Thesaurus Code: C96042 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL428376  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
NA-17/MAGE-3.A2/NY-ESO-1 Peptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 697137
PDQ Open Trial Search ID 697137 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C96042
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom